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1071-113 Effect of Carvedilol on Major Cardiovascular Events in 
Post-Infarction Patients Treated With Angiotensin 
Converting Enzyme Inhibitors: Further Analysis of the 
Capricorn Trial 
Jonathan Sackner-Bernstein, Ian Ford, Michele Robertson, Mary Ann Lukas, Milton 
Packer, Henry Dargie. St. Luke’sRoosevelt Hospital Center, New York, NY 
Background: The CAPRICORN trial evaluated the effect of carvedilol (CRV) on the risk 
of death and the combined risk of death or cardiovascular hospitakzation (CVH) in post- 
myocardial infarction (Ml) patients with left ventricular dysfunction receiving an ACE 
Inhibitor. CRV reduced the risk of death bv 23% (PzO.03) but reduced the risk of death or ~ 
CVH by only 9% (P=O.30). 
Methods: To explore the reasons for these findings, we analyzed the results of the CAP- 
RICORN trial using endpoints that had been used to show the efficacy of beta-blockers in 
other trials (post-MI beta-blocker trials and the COPERNICUS trial). In the COPERNI- 
CUS trial, the protocol-specified analysrs of CVH focused on major CVH (those for heart 
failure, MI or unstable angina, stroke or TIA, supraventricular or ventricular arrhythmia, 
bradycardia or heart block), whereas the prespecified definition in the CAPRICORN trial 
included all CVH (major or minor) except for procedures. 
Results: CRV reduced the risk of a major event when endpoints were analyzed that had 
been shown in earlier studies to be favorably influenced by beta-blockade. This included 
a 17% reduction in the risk of death or major CVH (defined as in the COPERNICUS 
trial)(P=O.OP). and significant reductions in the risk of fatal or non-fatal MI. 
Conclusions: These findings provide additional support for the efficacy of CRV in post- 
Ml patients already treated with an ACE inhibitor. 
All-cause mortakty 
Placebo 
(rl=984) 
151 
Nonfatal Ml 57 
Death (all-cause) or nonfatal Ml 192 
Fatal or nonfatal Ml 66 
Death or major CV hospitalization 
(COPERNICUS definition) 
327 
Carvedilol Hazard Ratio 
@l--975) (95% Cl) 
116 0.77 (0.60. 
0.98) 
34 0.59 (0.39- 
0.90) 
139 0.71 (0.57. 
0.89) 
40 0.60 (0.40- 
0.89) 
275 0.83 (0.70- 
0.97) 
P 
0.0 
31 
0.0 
14 
0.0 
02 
0.0 
098 
0.0 
19 
1071-114 Primary Angioplasty Reduces Mortality in Elderly 
Patients With Right Ventricular Infarction 
Georae S. Hansel. William W. O’Neill. Mark C. Pica, James A. Goldstein, William 
Beaumont Hospital, Royal Oak, Ml 
Background: In patients with acute right ventricular infarction (RVI), successful reperfu- 
sion by primary angioplasty improves hemodynamics and survival. Yet, it has been 
recently reported that RVI in elderly patients (2 70 years) is associated with in-hospital 
mortality -50%; however, such reports did not address reperfusion status. This study 
was designed to determine whether successful repetfusion exerts beneficial effects on 
mortality in elderly patients with RVI. Methodology: We studied 64 patients t 70 years 
old wth acute Inferior MI undergorng primary angioplasty. The presence of RVI was 
determined by 2D echo performed in the emergency department. In patients with and 
without RVI, we analyzed survival to hospital discharge according to reperfusion status 
(success defined as restoration of TIMI 3 flow). Results: In those with IMI but without RVI, 
reperfusion was successful in 35 (92%)pts, with survival to discharge in 94% of cases. 
RVI was detected in 26 (41%) pts, in whom reperfusron was successful in 21(81%) 
cases, resulting in survival to hospital discharge in 90% of pts which was similar to that 
achieved by reperfusion in IMI without RVI (90% vs. 94%, p = NS). In contrast, in pts with 
RVI but reperfusion failure, survival was strikingly lower (40% vs. 90%. p=O.O3). Conclu- 
sions: These results demonstrate that even in elderly pts with RVI. successful reperfu- 
sion by primary angioplasty is associated with excellent outcome, with survival similar to 
that achieved in IMI without RVI. In contrast, lack of successful reperfusion in the elderly 
wth RVI is associated with dismal outcome. 
1071-115 Female Gender Is the Strongest Predictor of Major 
Hemorrhage in Trials of Combination of Fibrinolytic and 
Glycoprotein IlbAlla Inhibitors 
Stephen D. Wwiott, Robert P. Giugliano, David A. Morrow, Uwe Zeymer. Matthew T. 
Roe, Robert A. Harrington, Brigham & Women’s Hospital, Boston, MA, Duke Clinical 
Research Institute. Durham, NC 
Background: Bleeding is the major adverse effect of modern pharmacologic therapy for 
myocardial infarction (Ml), and the major limitation of the use of combination fibrinolytic 
and GP Ilb/llla therapy. Identification of patients who are at Increased rusk for bleedrng is 
desirable to aid in decision-making regarding the use of these agents. We sought to 
examrne risk factors for bleeding in trials of the use of fibrinolytic +I- GP llbillla inhibitors 
for acute Ml. 
Methods: In hw AMI clinical trials (fibrinolytic +/- GP Ilb/llla Inhibitor) adludicated bleed- 
ing events using standard TIMI definitions were examined and compared to clinical char- 
acteristics. 
Results: of1573 patients (23% women), 97 patients (8.2%) had major hemorrhage (51 
women (14.2%) and 46 men (3.8%) odds ratio 4.2, Cl 2.8-6.4, PcO.OOl]. When adjusted 
for univariate predictors, female gender remained the strongest independent predictor of 
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major hemorrhage with a greater than three-fold increase in risk of major hemorrhage 
(table). 
Conclusions: Female gender is a significant risk factor for bleeding in AMI trials combin- 
rng fibrrnolytics and GP Ilb/llla inhibitors, independent of age, weight, and creatrnine 
clearance. Recognition of patients at increased risk for hemorrhage may aid in the choice 
of therapy for AMI, use of adjunctive therapies to reduce risk, and in designing future clin- 
ical trrals. 
Characteristic 
Gender (F) 
Age (10 Y) 
CrCl(l0 mkmin) 
Weight (10 kg) 
OR Cl Z P 
3.3 2.1 - 5.3 5.1 0.001 
1.5 1.2 - 1.8 2.5 0.02 
1.04 1.00-1.07 2.2 0.03 
0.89 0.76 - 1.03 -1.5 0.15 
1071-116 Do Baseline C-Reactive Protein Levels Predict 
Myocardial Salvage After Reperfusion Therapy in 
Patients With Acute Myocardial Infarction? 
Alban Dibra, Julinda Mehilli, Helmut Schuehlen, Juergen Pache, Jodi Neverve, Adnan 
Kastrati, Albert Schomig, Deutsches Herzzentrum Muenchen, Muenchen, Germany, 
Klinik fuer Nuklearmedizin rechts der Isa,, TU Muenchen, Germany 
The prognostic value of C-reactive protein (CRP) measured on admission in patients 
(pts) with acute myocardial infarction (AMI) treated with reperfusion therapies and its 
usefulness rn guiding the selection of the appropriate therapy are not known. We studied 
the relationship between baseline CRP and myocardial salvage (MS) in patients with AMI 
treated with reperfusion therapy and its therapeutical implications. The study population 
consisted in 302 pts of STOPAMI 1 and 2 randomized trials that compared stentrng (plus 
abcixmab) with thrombolysis (full-dose alone or half-dose plus abciximab) in AMI. CRP 
levels measured by a high sensitivity assay were available in 288 pts. The threshold of 
12 mgfdl (upper quartile limit) defined the group with high CRP (73 pts) and low CRP 
(215 pts). Two technetium-99m sestamibi studies were performed to calculate inrtial per- 
fusion defect, final infarct size and salvage index. Pts with high CRP had less MS (0.29 
vs. 0.47, P=O.O09) and higher l-year mortality (16.4% vs. 6.0%, P=O.O06) than pts with 
low CRP. The correlation between CRP and MS was confined to pts treated with throm- 
bolysis alone and was eliminated when stenting or thrombolysis were combined wrth 
abciximab (Figure). 
Conclusion: In pts with AMI, high CRP levels at baseline may be associated with less 
myocardial salvage achieved by reperfusion. Pts with high CRP may benefit from the 
addition of abciximab. 
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1072-100 Impact of Reocclusion on Long-Term Survival 
Following Fibrinolytic Therapy: lo-Year Follow-Up of 
the APRICOT-1 Trial 
Peter C. Kievit, Marc A. Brouwer, HendrikJan Dicker, Gerrit Veen. Freek W. A. 
Verheugt, Free University Medical Center, Amsterdam, The Netherlands, Heartcenter, 
University Medical Center, Nijmegen, The Netherlands 
Background: Reocclusion after successful fibrinolysis occurs in about 30% of patients, 
the majority in the absence of clintcal reinfarction: asymptomatic reocclusion. Whereas 
early symptomatic reocclusion has been associated with a twofold increased rusk of mor- 
tality, the prognostic impact of reocclus~on after the acute phase remains to be deter- 
mined. 
Methods: In the APRICOT-l trial 248 patients had an open infarct related artery at 
angiography < 48 hours, with follow-up angiography at 3 months. Outcome was recorded 
using medical charts and rnformation from the general physician and municipal registries. 
Results:: Reocclusion was observed in 71 patients (29%). Mean clinical follow-up was 
9.8c3.4 years, 71% having more than 10 years follow-up. No difference in death from 
any cause was observed between patients wrth and without reocclusion. However, lo- 
year cardiac death was higher in those with reocclusion: 22% vs. 11% (Figure, p = 0.06). 
This difference was primarily caused in the subset of patients in whom 3.month reccclu- 
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sion had occurred asymptomatically. 
Conclusions: After demonstrated coronary patency following fibrinolytic therapy, 
patients who survived the first 48 hours had an excellent IO-year prognosis. Whereas 
reocclusion was associated with a markedly increased risk of cardiac mortality, even in 
case of asymptomatic reocclus~on. all cause mortality did not differ from patients with 
sustained patency. 
1072-101 Management and Outcomes of Patients With Acute 
Coronary Syndromes: One-Year Results From the 
Canadian Acute Coronary Syndrome Registry 
Andrew T. Yan Shaun G. Goodman, Mary Tan, David Fltchett, Chi-Ming Chow, Anatoly 
Langer, Canadian ACS Registry Investigators, University of Toronto and Canadian Head 
Research Centre, Toronto, ON, Canada 
Background: While clinical trials provide evidence for the management of acute core- 
nary syndromes (ACS), these results may not be applicable to a wider patient population. 
There are limited data regarding the actual management and outcomes of patients dis- 
charged from hospitals following an ACS. 
Methods: The ACS Registry IS a prospective Canadian observational study of 5312 
patients wth suspected ACS from 51 centres in 9 provinces. A final diagnosis of ACS 
was determined in 4627 patients (87.1%). Vital status at l-year was available for 4329 
patients (6% lost to follow-up). Non-fatal cardiac events (myccardial infarction=Ml; unsta- 
ble angina=UA), angiography, and revascularization (percutaneous coronary interven- 
tion=PCI; coronary bypass surgery=CABG) after discharge (via standardized telephone 
interwew) were recorded for 3844 hospital discharge survivors at I-year follow-up. 
Results: One-year cumulative mortality was 9.2%. Treatment and unadjusted outcomes 
post-discharge for 3844 hospital survivors, classified by index discharge ACS diagnosis, 
were as follows: 
Post-discharge to 1 
year 
Death 
(re) MI 
Unstable Angina 
Angiography 
PCI 
CABG 
* p< 0.001 
All 0 Wave Ml Non-Q Ml UA (41%) 
patients (27%) (32%) 
7.2% 6.5% 10%’ 5.4% 
2.9% 2.7% 3.7% 2.6% 
8.0% 5.8% 6.4% 11%’ 
14% 15% 13% 14% 
6.8% 6.6% 6.6% 7.2% 
3.9% 4.3% 4.3% 3.3% 
Conclusions: Despite similar rates of in-hospital and post-discharge coronary angiogra- 
phy and revascularuation. unadjusted l-year mortality was higher in patients with non-Q 
wave Ml. This suggests that more aggressive therapy, including re-allocation of limited 
resources towards management of these high-risk patients, may be required. 
1072-102 Multiple Clinical Risk Factors Do Not Preclude 
Immediate Exercise Testing in a Chest Pain Evaluation 
Unit 
Ezra A. Amsterdam, Deborah Diercks, J. Douglas Kirk, University of California, Davis, 
Medical Center, Sacramento, CA 
BACKGROUND: In pabents (Pts) presenting with chest pain suggestive of acute coro- 
nary syndrome (ACS), low risk is associated with a nonischemic initial electrocardiogram 
and negative serum cardiac marker. To further refine risk assessment of these Pts. addi- 
tional clinical factors (ACF) have been utilized, as in the TIMI risk score. It has been sug- 
gested that Pts with aggregation of these risk factors should not be evaluated by an 
accelerated protocol in a chest pain evaluation unit (CPEU) because of a higher rate of 
ACS in this group. In our CPEU, we employ immediate exercise testing (IET) in Pts con- 
sidered low or intermediate risk based on the initial ECG and cardiac serum marker. We, 
therefore, reviewed our experience in Pts with ACF. 
METHODS: All Pts admItted to the CPEU had a normal initial ECG and negative initial 
Serum troponin I or myoglobln. We determined the relationship to Pt outcome of 2 1 of 
the following ACF: previously documented coronary artery disease, advanced age (>65 
yr) and presence of 2 3 CAD risk factors. Final diagnosis of ACS was based on evidence 
of CAD by further cardiac study (stress imaging or angiography) or occurrence of myo- 
cardval InfarctIon, revascularization or cardiac death durmg CPEU stay or 30 day follow- 
up (FU) period. 
RESULTS: IET was performed in 1808 consecutive Pts (919 man, 889 women. mean 
age 54 yr.) and was negative for lschemla in 65% (1168) of Pts. non-diagnostic (ND) in 
24% (427) and positive in 12% (213). There were no adverse effects of IET. There were 
1608 Pts with O-l ACF and 176 with 2-3 ACF. MultIpIe ACF predicted a positive or ND 
IET: 2 ACF (RR 4.2, Cl 2.8-6.3) and 3 ACF (RR 2.7, Cl 0.8-9.0). At 30 day FU there were 
no deaths and total cardiac events (non-Q Ml + revascularization) were: Pts with O-l ACF 
- 1.7%; Pts with 2-3 ACF - 7.0%. Revascularizatlon comprised 81% (30137) of all events. 
CONCLUSION: Aggregation of ACF is associated wth an increase in positive IET and 
cardiac events. However, there were no deaths and the number of events was very low, 
the majority of which were revascularization. Patients with ACF can be safely managed 
by the accelerated protocol in our CPEU. 
1072-l 03 Decline in Recurrent lschemic Events After Myocardial 
Infarction: A 20-Year Community Study 
Maan Jokhadar, Steven J. Jacobsen, Guy S. Reader, Susan A. Weston, Ryan 
Meverden, Jill M. Killian, Veronique L. Roger, Mayo Clinic, Rochester, MN 
Background: Despite use of efficacious interventions for secondary prevention after 
myocardial infarction (MI), little is known about their effect on the long-term incidence of 
recurrent ischemic events after MI. This study tested the hypothesis that recurrent 
lschemic events after incident Ml declined over time. 
Methods: Standard epidemiological criteria ware used to validate all incident MIS in Olm- 
sted County between 1979 and 1998. Recurrent ischemic events defined as recurrent 
MI. unstable angina requiring hospitalization (UA) and sudden cardiac death (SCD), were 
identified through the community medical record. 
Results: Between 1979 and 1998, 2277 incident Ml cases occurred I” Olmsted County 
(57% men; mean age, 672 14 years). After 6.3i 5.3 years of follow-up, there were 586 
recurrent MIS, 1025 UA, and 230 SCDs. The B-year event-free survival was 77% (95% 
Cl, 75%-79%) for recurrent MI, 53% (95% Cl%, 51.55%) for UA, and 93% (95% Cl, 92%. 
94%) for SCD. 
The table presents the relative risk (RR) of recurrent ischemlc events over time using 
subjects with Ml between 1979 and 19133 as the referent. Overall, all recurrent ischemic 
events decreased over time, in earlier years largely due to decline in recurrent Ml and UA 
whereas in most recent years, a marked decline in SCD occurred. 
Conclusion: Over the past 2 decades, the cxxurrence of recurrent lschemic events after 
incident Ml declined over time. most likely reflecting advances in therapy and secondary 
prevention. 
RR of recurrent ischemic events after MI in different time periods 
Recurrent Ml 
1979. 1984-l 988 
1983 
1 .oo 0.85 
(Cl 0.68-l .07) 
Unstable angina 
1 .oo 0.84 
(Cl 0.71-1.01) 
Any event 
1.00 1.04 
(Cl 0.75-I .45) 
1 .oo 0.89 
(Cl 0.76-1.04) 
1989-l 993 1994-I 996 
0.76 
(Cl 0.60-0.96) 
0.93 
(Cl 0.78-1.10) 
0.87 
(Cl 0.61-I .26) 
0.89 
(Cl 0.76-I .04) 
0.79 
(Cl 0.62-1.02) 
0.81 
(Cl 0.68-0.97) 
0.40 
(Cl 0.24-0.67) 
0.76 
(Cl 0.66-0.93) 
1072-104 The TIMI Risk Index Predicts Long-Term Mortality in 
Patients Admitted With Primary Unstable Angina 
David O’Halloran Christopher J. O’Donnell. Robert P. Giugliano, Carlos A. Camargo, Jr., 
Larry Allen, Donald M. Lloyd-Jones, Massachusetts General Hospital, Boston, MA 
Background:The Thrombolysis In Myocardial lschemia (TIMI) risk index - [(heart rate x 
(agellO~)isystolic blood pressure] has been shown to be a strong and independent 
predictor of 30.day mortality in selected patients presenting with ST-elevation MI, but its 
utility for unselected patients presenting with unstable angina (UA) and its ability to pre- 
dict long term outcomes are unknown. 
Methods: We updated a pre-existing database of 280 unselected patients with primary 
UA admitted via the Emergency Department to a large, urban academic hospital in 1991- 
1992. We calculated the TIMI risk index for each patient based on values at presentation 
and used Cox models to assess the ability of the risk Index to predict long-term mortality. 
Results: There were 275 patients (age 66+12 years, 33% women) who survived to hos- 
pital discharge. Post-discharge death was documented in 134 patients. VItaI status was 
known for >99% of patients at 1 year, 86% at 5 years and 77% at IO years. Median fol- 
low-up for patients who did not die was 9.4 years. The mean risk index was 23tlO points 
(range 5-65). The risk index was a strong predictor of l-year and lo-year mortality 
(p=O.O02). For each IO-point increase in the risk index, the hazard ratio for one year mor- 
tality was 1.61 (95% Cl 1.23 - 2.10) and the hazard ratio for 10 year mortality was 1.72. 
(95% Cl 1.51 - 1.96). We found optimal discrimination for 1 O-year mortality using a cut- 
point of 21 points (=21 vs. ~21: hazard ratio (HR) 4.3, 95% Cl 2.9-6.4). Compared with 
the lowest quintile of risk index, the HR for IO-year mortality for the highest qulntile was 
5.5 (95% Cl 3.0-10.0). After multivariable adjustment for other known predictors of IO- 
year mortality (CHF. elevated creatinine or kukocytosis at presentation, history of diabe- 
tes mellitus or Ml), the risk index remained a significant predictor of 1 O-year moltality (HR 
for IO-point increase: 1.5, 95% Cl 1.3-I 3). 
